Recent advances of MEK inhibitors and their clinical progress

Current Topics in Medicinal Chemistry

Volumn 7, Issue 14, 2007, Pages 1364-1378

  Wang, John ^a   Wilcoxen, Keith M ^a   Nomoto, Kenichi ^a   Wu, Sara ^b  

^a EISAI RESEARCH INSTITUTE   (United States)

^b EISAI INC   (United States)

Author keywords

AZD6244; B RAF mutation; Hypothemycin; MEK inhibitors; MEK kinase; PD0325901; RAF kinase; Resorcylic acid lactones

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ADENOSINE TRIPHOSPHATE; ARRY 142886; AZD 6244; BEVACIZUMAB; CETUXIMAB; CHIR 265; ERLOTINIB; GEFITINIB; GW 5074; HYMENIALDISINE; HYPOTHEMYCIN; L 779450; L 783277; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PLX 4032; PROTEIN KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; RO 092210; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG ERUPTION; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; HYPOXIA; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER FUNCTION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NAUSEA; OVARY CANCER; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA; VISUAL DISORDER; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 34548822459     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607781696837     Document Type: Review

References (70)

1. Thompson, N.; Lyons, J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr. Opin. Pharmacol., 2005, 5, 350-356.
2. Hoshino, R.; Chatani, Y.; Yamori, T.; Tsuruo, T.; Oka, H.; Yoshida, O.; Shimada, Y.; Ari-i, S.; Wada, H.; Fujimoto, J.; Kohno, M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene, 1999, 18, 813-822.
3. McCubrey, J.A.; Steelman, L.S.; Abrams, S.L.; Lee, J.T.; Chang, F.; Bertrand, F.E.; Navolanic, P.M.; Terrian, D.M.; Franklin, R.A.; D'Assoro, A.B.; Salisbury, J.L.; Mazzarino, M.C.; Stivala, F.; Libra, M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enz. Regul., 2006 46, 249-279.
4. Weinstein-Oppenheimer, C.R.; Blalock, W.L.; Steelman, L.S.; Chang, F.; McCubrey, J.A. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol. Therapeut., 2001, 88, 229-279.
5. Arora, A.; Scholar, E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exper. Therapeut., 2005, 315 971-979.
6. Sridhar, S.S.; Hedley, D.; Siu, L.L. Raf kinase as a target for anticancer therapeutics. Mol. Can. Therapeut., 2005, 4 677-685.
7. Smith, R.A.; Dumas, J.; Adnane, L.; Wilhelm, S.M. Recent advances in the research and development of RAF kinase inhibitors. Curr. Top. Med. Chem., 2006, 6, 1071-1089.
8. Sacks, D.B. The role of scaffold proteins in MEK/ERK signalling. Biochem. Soc. Trans., 2006, 34, 833-836.
9. Fujioka, A.; Terai, K.; Itoh, R.E.; Aoki, K.; Nakamura, T.; Kuroda, S.; Nishida, E.; Matsuda, M. Dynamics of the Ras/ERK MAPK Cascade as Monitored by Fluorescent Probes. J. Biol. Chem., 2006, 281, 8917-8926.
10. Kolch, W. Coordinating ERK/MAPK signaling through scaffold and inhibitors. Nat. Rev. Mol. Cell Biol., 2005, 6, 827-837.
11. Chong, H.; Vikis, H.G.; Guan, K.-L. Mechanisms of regulating the Raf kinase family. Cell. Signal., 2003, 15, 463-469.
12. Kolch, W. Ras/Raf signalling and emerging pharmacotherapeutic targets. Exp. Opin. Pharmacother., 2002, 3, 709-718.
13. Clark, G.J.; O'Bryan, J.P.; Der, C.J. Ras signaling and transformation. Signal. Networks Cell Cycle Control., 2000, 213-230.
14. Tibbles, L.A.; Woodgett, J.R. The stress-activated protein kinase pathways. Cell. Mol. Life Sci., 1999, 55, 1230-1254
15. Webb, C.P.; Van Aelst, L.; Wigler, M.H.; Vande Woude, G.F. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA, 1998, 95, 8773-8779.
16. Kerkhoff, E.; Houben, R.; Loffler, S.; Troppmair, J.; Lee, J.-E.; Rapp, U.R. Regulation of c-myc expression by Ras/Raf signalling. Oncogene, 1998, 16, 211-216.
17. Vanderkuur, J.A.; Butch, E.R.; Waters, S.B.; Pessin, J.E.; Guan, K.-L.; Carter-Su, C. Signaling molecules involved in coupling growth hormone receptor to mitogen-activated protein kinase activation. Endocrinology, 1997, 138, 4301-4307.
18. Macdonald, S.G.; McCormick, F. The RAS/RAF/ERK signal transduction pathway. Front. Mol. Biol., 1997, 19, 121-153.
19. Macdonald, S.G.; Crews, C.M.; Wu, L.; Driller, J.; Clark, R.; Erikson, R.L.; McCormick, F. Reconstitution of the Raf-1-MEKERK signal transduction pathway in vitro. Mol. Cell. Biol., 1993, 13, 6615-6620.
20. Hagemann, C.; Blank, J.L. The ups and downs of MEK kinase interactions. Cell. Signal., 2001, 13, 863-875.
21. Roy, F.; Laberge, G.; Douziech, M.; Ferland-McCollough, D.; Therrien, M. KSR is a scaffold required for activation of the ERK/MAPK module. Genes Develop., 2002, 16, 427-438.
22. Wang, X.; Studzinski, G.P. Phosphorylation of Raf-1 by Kinase Suppressor of Ras Is Inhibited by "MEK-Specific" Inhibitors PD 098059 and U0126 in Differentiating HL60 Cells. Exper. Cell Res., 2001, 268, 294-300.
23. Miyamoto, S.; Teramoto, H.; Coso, O.A.; Gutkind, J.S.; Burbelo, P.D.; Akiyama, S.K.; Yamada, K.M. Integrin function: Molecular hierarchies of cytoskeletal and signaling molecules. J. Cell Biol., 1995 131, 791-805.
24. Vomastek, T.; Schaeffer, H.-J.; Tarcsafalvi, A.; Smolkin, M.E.; Bissonette, E.A.; Weber, M.J. Modular construction of a signaling scaffold: MORG1 interacts with components of the ERK cascade and links ERK signaling to specific agonists. Proc. Natl. Acad. Sci. USA, 2004, 101, 6981-6986.
25. Davies, H.; Bignell, G.R.; Cox, C.; Stephens, P.; Edkins, S.; Clegg, S.; Teague, J.; Woffendin, H.; Garnett, M.J.; Bottomley, W.; Davis, N.; Dicks, E.; Ewing, R.; Floyd, Y.; Gray, K.; Hall, S.; Hawes, R.; Hughes, J.; Kosmidou, V.; Menzies, A.; Mould, C.; Parker, A.; Stevens, C.; Watt, S.; Hooper, S.; Wilson, R.; Jayatilake, H.; Gusterson, B.A.; Cooper, C.; Shipley, J.; Hargrave, D.; Pritchard-Jones, K.; Maitland, N.; Chenevix-Trench, G.; Riggins, G.J.; Bigner, D.D.; Palmieri, G.; Cossu, A.; Flanagan, A.; Nicholson, A.; Ho, J.W.C.; Leung, S.Y.; Yuen, S.T.; Weber, B.L.; Seigler, H.F.; Darrow, T.L.; Paterson, H.; Marais, R.; Marshall, C.J.; Wooster, R.; Stratton, M.R.; Futreal, P.A. Mutations of the BRAF gene in human cancer. Nature (London, United Kingdom), 2002, 417, 949-954.
26. Lee, J.T. Jr.; McCubrey, J.A. Targeting the Raf kinase cascade in cancer therapy - novel molecular targets and therapeutic strategies. Exp. Opin. Ther. Targets, 2002, 6, 659-678.
27. Kalofonos, H.P.; Grivas, P.D. Monoclonal antibodies in the management of solid tumors. Curr. Top. Med. Chem., 2006, 6, 1687-1705.
28. Weiner, L.M.; Borghaei, H. Targeted therapies in solid tumors: Monoclonal antibodies and small molecules. Human Antibodies, 2006, 15, 103-111.
29. Gatto, B. Monoclonal antibodies in cancer therapy. Curr. Med. Chem. Anti-Cancer Agents, 2004, 4, 411-414.
30. Johnston, J.B.; Navaratnam, S.; Pitz, M.W.; Maniate, J.M.; Wiechec, E.; Baust, H.; Gingerich, J.; Skliris, G.P.; Murphy, L.C.; Los, M. Targeting the EGFR pathway for cancer therapy. Curr. Med. Chem., 2006 13, 3483-3492.
31. Settleman, J. Inhibition of mutant EGF receptors by gefitinib. Targeting an Achilles' heel of lung cancer. Cell Cycle, 2004, 3 1496-1497.
32. Tang, P.A.; Tsao, M.-S.; Moore, M.J. A review of erlotinib and its clinical use. Exp. Opin. Pharmacother., 2006, 7, 177-193.
33. Oka, H.; Chatani, Y.; Hoshino, R.; Ogawa, O.; Kakehi, Y.; Terahi, T.; Okada, Y.; Kawaichi, M.; Kohno, M.; Yoshida, O. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res., 1995, 55, 4182-4187.
34. Wan, P.T.C.; Garnett, M.J.; Roe, S.M.; Lee, S.; Niculescu-Duvaz, D.; Good, V.M.; Jones, C.M.; Marshall, C.J.; Springer, C.J.; Barford, D.; Marais, R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell, 2004, 116, 855-867.
35. Wooster, R.; Futreal, A.P.; Stratton, M.R. Sequencing Analysis of BRAF Mutations in Human Cancers. Methods Enzymol., 2005, 407, 218-224.
36. Solit, D.B.; Garraway, L.A.; Pratilas, C.A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J.M.; She, Y.; Osman, I.; Golub, T.R.; Sebolt-Leopold, J.; Sellers, W.R.; Rosen, N. BRAF mutation predicts sensitivity to MEK inhibition. Nature (London, United Kingdom), 2006, 439 358-362.
37. Chang, F.; Steelman, L.S.; Shelton, J.G.; Lee, J.T.; Navolanic, P.M.; Blalock, W.L.; Franklin, R.; McCubrey, J.A. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (review). Int. J. Oncol., 2003, 22, 469-480.
38. Fukushima, T.; Suzuki, S.; Mashiko, M.; Ohtake, T.; Endo, Y.; Takebayashi, Y.; Sekikawa, K.; Hagiwara, K.; Takenoshita, S. BRAF mutations in papillary carcinomas of the thyroid. Oncogene, 2003, 22, 6455-6457.
39. Aust, D.E.; Haase, M.; Dobryden, L.; Markwarth, A.; Loehrs, U.; Wittekind, C.; Baretton, G.B.; Tannapfel, A. Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. Int. J. Cancer 2005, 115, 673-677.
40. Basto, D.; Trovisco, V.; Lopes, J.M.; Martins, A.; Pardal, F.; Soares, P.; Reis, R.M. Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathologica, 2005, 109, 207-210.
41. Cho, N.-Y.; Choi, M.; Kim, B.-H.; Cho, Y.-M.; Moon, K.C.; Kang, G.H. BRAF and KRAS mutations in prostatic adenocarcinoma. Int. J. Cancer, 2006, 119, 1858-1862.
42. Karasarides, M.; Chiloeches, A.; Hayward, R.; Niculescu-Duvaz, D.; Scanlon, I.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Martin, J.; Marshall, C.J.; Springer, C.J.; Marais, R. B-RAF is a therapeutic target in melanoma. Oncogene, 2004, 23, 6292-6298.
43. Sorbera, L.A.; Castaner, J.; Bozzo, J.; Leeson, P.A. Oncolytic Raf kinase inhibitor. Drugs Future, 2002, 27, 1141-1147
44. Wilhelm, S.; Carter, C.; Lynch, M.; Lowinger, T.; Dumas, J.; Smith, R.A.; Schwartz, B.; Simantov, R.; Kelley, S. Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov., 2006, 5, 835-844.
45. Ibrahim, P.N.; Zhang, J.; Cho, H.; Mamo, S.; Bremer, R.; Gillette, S.; Kumar, A.; Fong, D.; Wang, W.; Zhu, Y.-L.; Marimuthu, A.; Suzuki, Y.; Lam, B.; Rice, J.; Tsai, J.; Settachatgul, C.; Shelloe, R.; Cantwell, J.; West, B.; Powell, B.; Habets, G.; Zhang, C.; Artis, D.R.; Hirth, P.; Bollag, G. Discovery and pre-clinical development of a novel inhibitor of oncogenic B-Raf. Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, 2006 2006:MEDI.
46. Yue, X.; Varga, E.V.; Stropova, D.; Vanderah, T.W.; Yamamura, H.I.; Roeske, W.R. Chronic morphine-mediated adenylyl cyclase superactivation is attenuated by the Raf-1 inhibitor, GW5074. Eur. J. Pharmacol. 2006, 540, 57-59.
47. Van Gompel, J.J.; Kunnimalaiyaan, M.; Holen, K.; Chen, H. ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol. Cancer Therapeut., 2005, 4 910-917.
48. Wallace, E.M.; Lyssikatos, J.P.; Yeh, T.; Winkler, J.D.; Koch, K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr. Top. Med. Chem., 2005, 5, 215-229.
49. Solit, D.B.; Garraway, L.A.; Pratilas, C.A.; Sawai, A.; Getz, G.; Basso, A.; Ye, Q.; Lobo, J.M.; She, Y.; Osman, I.; Golub, T.R.; Sebolt-Leopold, J.; Sellers, W.R.; Rosen, N. BRAF mutation predicts sensitivity to MEK inhibition. Nature, 2006, 439, 358-362.
50. Lorusso, P.; Krishnamurthi, S.; Rinehart, J.; Nabell, L.; Croghan, G.; Varterasian, M.; Sadis S.; Menon, J.; Leopold, J.; Meyer, M. A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD0325901 in patients with advanced cancer. ASCO Annual Meeting, 2005.
51. Lorusso, P. MEK as a therapeutic target in human cancer. 97th AACR Annual Conference. Washington, D.C., 2006.
52. LoRusso, P.M.; Adjei, A.A.; Varterasian, M.; Gadgeel, S.; Reid, J.; Mitchell, D.Y.; Hanson, L.; DeLuca, P.; Bruzek, L.; Piens, J.; Asbury, P.; Van Becelaere, K.; Herrera, R.; Sebolt-Leopold, J.; Meyer, M.B. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol., 2005 23, 5281-5293.
53. Alan, P.; Brown, J.F.R.; Lonnie, G.; Cho-Ming, L.; Keri, V. B.; Judy, L.; Michael, J.G. Pharmacologic Inhibitors of the MEK-MAP Kinase Pathway are Associated with Toxicity to the Skin, Stomach, Intestines and Liver. AACR 2006 annual meeting Washington, D.C., 2006.
54. Han, S.; Zhou, V.; Pan, S.; Liu, Y.; Hornsby, M.; McMullan, D.; Klock, H.E.; Haugen, J.; Lesley, S.A.; Gray, N.; Caldwell, J.; Gu, X.-j. Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg. Med. Chem. Lett., 2005, 15 5467-5473.
55. Koch, K.; Hurley, T.B.; Yang, H.W.; Lyssikatos, J.; Blake, J.F.; Marlow, A.L.; Wallace, E.M. Preparation of fused (is)oxazoles and analogs as inhibitors of MEK kinase. Application: US: 2006030610 (USA). 2006. p.79 pp.
56. Wallace, E.M.; Lyssikatos, J.; Blake, J.F.; Seo, J.; Yang, H.W.; Yeh, T.C.; Perrier, M.; Jarski, H.; Marsh, V.; Poch, G.; Livingston, M.G.; Otten, J.; Hingorani, G.; Woessner, R.; Lee, P.; Winkler, J.; Koch, K. Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones. J. Med. Chem., 2006, 49, 441-444.
57. Ohren, J.F.; Chen, H.; Pavlovsky, A.; Whitehead, C.; Zhang, E.; Kuffa, P.; Yan, C.; McConnell, P.; Spessard, C.; Banotai, C.; Mueller, W.T.; Delaney, A.; Omer, C.; Sebolt-Leopold, J.; Dudley, D.T.; Leung, I.K.; Flamme, C.; Warmus, J.; Kaufman, M.; Barrett, S.; Tecle, H.; Hasemann, C.A. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol. 2004, 11, 1192-1197.
58. Kao, C.-Y.; Huang, F.; Chen, Y.; Thai, P.; Wachi, S.; Kim, C.; Tam, L.; Wu, R. Up-Regulation of CC Chemokine Ligand 20 Expression in Human Airway Epithelium by IL-17 through a JAK-Independent but MEK/ NF-kB-Dependent Signaling Pathway. J. Immunol., 2005, 175, 6676-6685.
59. Lin, D.A.; Boyce, J.A. IL-4 Regulates MEK Expression Required for Lysophosphatidic Acid-Mediated Chemokine Generation by Human Mast Cells. J. Immunol., 2005, 175, 5430-5438.
60. Wang, Z.-Q.; Wu, D.-C.; Huang, F.-P.; Yang, G.-Y. Inhibition of MEK/ERK 1/2 pathway reduces pro-inflammatory cytokine interleukin-1 expression in focal cerebral ischemia. Brain Res., 2004, 996, 55-66.
61. Abdellaoui, H.; Tam, R.; Chen, H.; Chamakura, V.; Barawkar, D.; Maderna, A.; Hong, Z.; Lang, S. Preparation of 5-phenylaminoisothiazole-4-carboxamidines as MEK inhibitors. Application: US: 2006194802 (USA). 2006 pp. 255.
62. Abdellaoui, H.; Varaprasad, C.V.N.S.; Barawkar, D.; Chakravarty, S.; Maderna, A.; Tam, R.; Chen, H.; Allan, M.; Wu, J.Z. Appleby, T.; Yan, S.; Zhang, W.; Lang, S.; Yao, N.; Hamatake, R.; Hong, Z. Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg. Med. Chem. Lett., 2006 16, 5561-5566.
63. Goutopoulos, A.; Sutton, A.; Karra, S.; Xu, Q.; Fischer, D.; Zhang, W.; Hum, C.; Brugger, N.; Healey, B.; Luo, Z.; McGregor, M.; Jiang, X.; Ramamurthy, A.; Murray, R.; Magar, S.; Blume-Jensen, P.; Zhang, J.; Nabioullin, R.; Arulandandam, T.; Tepper, M.; Askew, B.; Arkinstall, S.; Marinelli, P.; Golzio, L.; Giachetti, C.; Schwarz, M. Novel, orally bioavailable N-substituted imidazole-based MEK inhibitors as potential anticancer agents. Abstracts of Papers, 232nd ACS National Meeting, San Francisco, CA, United States, 2006.
64. Zhao, A.; Lee, S.H.; Mojena, M.; Jenkins, R.G.; Patrick, D.R.; Huber, H.E.; Goetz, M.A.; Hensens, O.D.; Zink, D.L.; Vilella, D.; Dombrowski, A.W.; Lingham, R.B.; Huang, L. Resorcylic acid lactones: Naturally occurring potent and selective inhibitors of MEK. J. Antibiot., 1999, 52, 1086-1094.
65. Takehana, K.; Sato, S.-i.; Kobayasi, T.; Maeda, T. A Radicicol-Related Macrocyclic Nonaketide Compound, Antibiotic LL-Z1640-2, Inhibits the JNK/ p38 Pathways in Signal-Specific Manner. Biochem. Biophys. Res. Commun., 1999, 257, 19-23.
66. Williams, D.H.; Wilkinson, S.E.; Purton, T.; Lamont, A.; Flotow, H.; Murray, E.J. Ro 09-2210 exhibits potent anti-proliferative effects on activated T cells by selectively blocking MKK activity. Biochemistry, 1998, 37, 9579-9585.
67. Santi, D.V.; Reid, R.C.; Hutchinson, R.C.; Sundermann, K.F.; Lau, J. Resorcylic acid lactone kinase inhibitors, and their therapeutic use for the treatment of cancers and other conditions. Application: WO: 2006036941 (Kosan Biosciences Incorporated, USA). 2006. p.110 pp.
68. Schirmer, A.; Kennedy, J.; Murli, S.; Reid, R.; Santi, D.V. Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. Proc. Natl. Acad. Sci. USA, 2006, 103, 4234-4239.
69. Wee, J.L.; Sundermann, K.; Licari, P.; Galazzo, J. Cytotoxic Hypothe-mycin Analogues from Hypomyces subiculosus. J. Nat. Prod. 2006, 69, 1456-1459.
70. Tanaka, H.; Nishida, K.; Sugita, K.; Yoshioka, T. Antitumor efficacy of hypothemycin, A new ras-signaling inhibitor. Japanese J. Cancer Res., 1999, 90, 1139-1145.